Cargando…

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia

BACKGROUND: The time‐limited combination of venetoclax and obinutuzumab (VenG) was established by the German CLL Study Group in the CLL14 trial for the upfront management of newly diagnosed chronic lymphocytic leukemia (CLL), showing a superior progression free survival benefit. The incidence of gra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samuels, Courtney, Abbott, Diana, Niemiec, Sierra, Tobin, Jennifer, Falco, Angela, Halsema, Keri, Kamdar, Manali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124494/ https://www.ncbi.nlm.nih.gov/pubmed/34250757 http://dx.doi.org/10.1002/cnr2.1505

Ejemplares similares

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
por: Kanevsky, D., et al.
Publicado: (2022)

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
por: Chatterjee, Anuja, et al.
Publicado: (2022)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time‐limited venetoclax/obinutuzumab treatment
por: Dimou, Maria, et al.
Publicado: (2021)

Obinutuzumab treatment in the elderly patient with chronic lymphocytic leukemia
por: Seiter, Karen, et al.
Publicado: (2015)

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia
por: Luan, Chunyan, et al.
Publicado: (2019)

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen
por: Thompson, Meghan C., et al.
Publicado: (2022)

Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia
por: Sharman, Jeff P., et al.
Publicado: (2022)

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
por: Samineni, Divya, et al.
Publicado: (2022)

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Hengeveld, Paul, et al.
Publicado: (2023)

New developments in the treatment of chronic lymphocytic leukemia: role of obinutuzumab
por: Shah, Arpita
Publicado: (2015)

Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
por: Smolej, Lukáš
Publicado: (2014)

Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy
por: Al-Sawaf, Othman, et al.
Publicado: (2017)

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
por: Khurana, Sharad, et al.
Publicado: (2019)

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
por: Chatterjee, Anuja, et al.
Publicado: (2021)

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
por: Hill, Brian T, et al.
Publicado: (2015)

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia
por: Cerquozzi, Sonia, et al.
Publicado: (2015)

Obinutuzumab in a patient with chronic lymphocytic leukemia-associated paraneoplastic pemphigus
por: Freund, Johanna, et al.
Publicado: (2022)

Obinutuzumab‐induced serum sickness following salvage therapy for chronic lymphocytic leukemia
por: Saba, Julie, et al.
Publicado: (2017)

Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia
por: Muhowski, Elizabeth M., et al.
Publicado: (2022)

The expanding role of venetoclax in chronic lymphocytic leukemia and small lymphocytic lymphoma
por: Schieber, Michael, et al.
Publicado: (2019)

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia
por: Evans, Sarah S., et al.
Publicado: (2015)

Obinutuzumab: A FDA approved monoclonal antibody in the treatment of untreated chronic lymphocytic leukemia
por: Sachdeva, Mamta, et al.
Publicado: (2015)

Efficacy and Safety of the Combination of Tirabrutinib and Entospletinib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia
por: Kutsch, Nadine, et al.
Publicado: (2022)

Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
por: Kittai, Adam S., et al.
Publicado: (2021)

Posterior Reversible Encephalopathy Syndrome Triggered by Obinutuzumab in a Patient with Chronic Lymphocytic Leukemia
por: Atef, Bentolhoda, et al.
Publicado: (2023)

Pulmonary Mucormycosis in Chronic Lymphocytic Leukemia and Neutropenia
por: Mir, Izza, et al.
Publicado: (2018)

Successful Retreatment With Venetoclax in a Patient With Chronic Lymphocytic Leukemia
por: Jackson, Ross A., et al.
Publicado: (2022)

Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumab
por: Jain, Punit, et al.
Publicado: (2016)

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study
por: Fresa, Alberto, et al.
Publicado: (2022)

Successful treatment of hairy cell leukemia variant with obinutuzumab
por: Al-Sarayfi, Diana, et al.
Publicado: (2021)

First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
por: Moreno, Carol, et al.
Publicado: (2022)

Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
por: Herling, Carmen D., et al.
Publicado: (2018)

Venetoclax in the Treatment of Chronic Lymphocytic Leukemia: Evidence, Expectations, and Future Prospects
por: Tariq, Saba, et al.
Publicado: (2020)

Venetoclax: a real game changer in treatment of chronic lymphocytic leukemia
por: Molica, Stefano
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_65eekc7f1e2cgvrb5qbdp8pfhu